Multiple Approaches Converge on Three Biological Subtypes of Meningioma and Extract New Insights From Published Studies

Authors

James C Bayley
Caroline C Hadley
Arif O Harmanci
Akdes S Harmanci
Tiemo J Klisch
Akash J Patel

Publication Date

2-4-2022

Journal

Science Advances

Abstract

One-fifth of meningiomas classified as benign by World Health Organization (WHO) histopathological grading will behave malignantly. To better diagnose these tumors, several groups turned to DNA methylation, whereas we combined RNA-sequencing (RNA-seq) and cytogenetics. Both approaches were more accurate than histopathology in identifying aggressive tumors, but whether they revealed similar tumor types was unclear. We therefore performed unbiased DNA methylation, RNA-seq, and cytogenetic profiling on 110 primary meningiomas WHO grade I and II). Each technique distinguished the same three groups (two benign and one malignant) as our previous molecular classification; integrating these methods into one classifier further improved accuracy. Computational modeling revealed strong correlations between transcription and cytogenetic changes, particularly loss of chromosome 1p, in malignant tumors. Applying our classifier to data from previous studies also resolved certain anomalies entailed by grouping tumors by WHO grade. Accurate classification will therefore elucidate meningioma biology as well as improve diagnosis and prognosis.

Keywords

DNA Methylation, Humans, Meningeal Neoplasms, Meningioma, Plant Extracts, Prognosis

DOI

10.1126/sciadv.abm6247

PMID

35108039

PMCID

PMC11313601

PubMedCentral® Posted Date

2-2-2022

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes